SCHEMBL29444624

SCHEMBL29444624

CCn1cnc2c(Nc3cccc(Cl)c3)nc(Cl)nc21

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.74
CDK1 P06493 12/20 0.70
PRKCA P17252 5/20 0.70
CLK1 P49759 3/20 0.62
CLK2 P49760 3/20 0.62
CCNB1 P14635 3/20 0.62
CCNE1 P24864 3/20 0.62
CDK2 P24941 3/20 0.62
CLK4 Q9HAZ1 2/20 0.62
EGFR P00533 2/20 0.62
CCNT1 O60563 1/20 0.62
CDK4 P11802 1/20 0.62
EIF2AK2 P19525 1/20 0.62
CCNA2 P20248 1/20 0.62
CCND1 P24385 1/20 0.62
CCND3 P30281 1/20 0.62
MTOR P42345 1/20 0.62
CDK7 P50613 1/20 0.62
CDK9 P50750 1/20 0.62
RAB9A P51151 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3352454 1.00 NPC1 (0.74) NPC1CDK1PRKCACLK1CLK2
SCHEMBL5840317 0.88 CDK1 (0.68) NPC1CDK1PRKCACLK1CLK2
SCHEMBL3379300 0.88 YTHDC1 (0.60) NPC1CDK1PRKCACDK2CCNA2
SCHEMBL5839410 0.86 CDK1 (0.69) NPC1CDK1PRKCACLK1CLK2
SCHEMBL5839910 0.86 CDK1 (0.69) NPC1CDK1PRKCACLK1CLK2
SCHEMBL3346901 0.85 NPC1 (1.00) NPC1CDK1PRKCACLK1CLK2
SCHEMBL5840706 0.85 CDK1 (0.69) NPC1CDK1PRKCACLK1CLK2
SCHEMBL183315 0.85 SRC (0.61) NPC1CDK1PRKCACCNE1CDK2
SCHEMBL5840456 0.85 CDK1 (0.75) NPC1CDK1PRKCACLK1CLK2
SCHEMBL244036 0.84 SRC (0.55) NPC1CDK1PRKCACCNB1CDK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114149432-B Dual CLK/CDK1 inhibitors for cancer treatment 斯坦福国际研究院 2024-07-05 CN disclosed
EP-4086257-A1 DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT SRI International (US) 2022-11-09 EP disclosed
CN-114149432-A Dual CLK/CDK1 inhibitors for cancer treatment 斯坦福国际研究院 2022-03-08 CN disclosed